Cargando…

Correction: Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria

Detalles Bibliográficos
Autores principales:	Bada, Florence O., Blok, Nick, Okpokoro, Evaezi, Dutt, Saswata, Akolo, Christopher, Dakum, Patrick, Abimiku, Alash’le
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553159/ https://www.ncbi.nlm.nih.gov/pubmed/34710200 http://dx.doi.org/10.1371/journal.pone.0259492

Ejemplares similares

Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria
por: Bada, Florence O., et al.
Publicado: (2020)

Cost of three models of care for drug-resistant tuberculosis patients in Nigeria
por: Bada, Florence O., et al.
Publicado: (2019)

Development of a prospective cohort of HIV Exposed Sero-Negative (HESN) individuals in Jos Nigeria
por: Osawe, Sophia, et al.
Publicado: (2016)

Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries
por: Schwœbel, Valérie, et al.
Publicado: (2020)

Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria
por: Anude, Chuka J, et al.
Publicado: (2013)

Diagnostic system strengthening for drug resistant tuberculosis in Nigeria: impact and challenges
por: Aliyu, Gambo, et al.
Publicado: (2017)

Performance and trend for quality of service in a large HIV/AIDS treatment program in Nigeria
por: Aliyu, Ahmad, et al.
Publicado: (2019)

A23 Identification of HIV drug resistance mutation patterns using illumina MiSeq next generation sequencing in patients failing second-line boosted protease inhibitor therapy in Nigeria
por: James, Onyemata E., et al.
Publicado: (2017)

Community stakeholder engagement during a vaccine demonstration project in Nigeria: lessons on implementation of the good participatory practice guidelines
por: Folayan, Morenike Oluwatoyin, et al.
Publicado: (2019)

Prevalence and characteristics of metabolic syndrome and its components among adults living with and without HIV in Nigeria: a single-center study
por: Jumare, Jibreel, et al.
Publicado: (2023)

Effectiveness and safety of bedaquiline-based, modified all-oral 9–11-month treatment regimen for rifampicin-resistant tuberculosis in Vietnam
por: Nguyen, Thi Mai Phuong, et al.
Publicado: (2023)

Primary Health Care: A Necessity in Developing Countries?
por: Okpokoro, Evaezi
Publicado: (2013)

Factors associated with receipt of a timely infant birth dose of hepatitis B vaccine at a tertiary hospital in North-Central Nigeria
por: Bada, Florence O., et al.
Publicado: (2022)

Characterisation of HIV-1 Molecular Epidemiology in Nigeria: Origin, Diversity, Demography and Geographic Spread
por: Nazziwa, Jamirah, et al.
Publicado: (2020)

Effect of community antiretroviral therapy on treatment outcomes among stable antiretroviral therapy patients in Nigeria: A quasi experimental study
por: Dakum, Patrick, et al.
Publicado: (2021)

Missed opportunities for early infant diagnosis of HIV in rural North-Central Nigeria: A cascade analysis from the INSPIRE MoMent study
por: Anaba, Udochisom C., et al.
Publicado: (2019)

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis
por: Sweeney, Sedona, et al.
Publicado: (2022)

HIV Coinfection Is Associated with Low-Fitness rpoB Variants in Rifampicin-Resistant Mycobacterium tuberculosis
por: Loiseau, Chloé, et al.
Publicado: (2020)

Mycobacterial Etiology of Pulmonary Tuberculosis and Association with HIV Infection and Multidrug Resistance in Northern Nigeria
por: Aliyu, Gambo, et al.
Publicado: (2013)

Injectables’ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes
por: Decroo, Tom, et al.
Publicado: (2020)

Prevalence of hypertension among patients aged 50 and older living with human immunodeficiency virus
por: Dakum, Patrick, et al.
Publicado: (2019)

High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa
por: Hirasen, Kamban, et al.
Publicado: (2018)

Cost-effectiveness of point-of-care digital chest-x-ray in HIV patients with pulmonary mycobacterial infections in Nigeria
por: Aliyu, Gambo, et al.
Publicado: (2014)

Prevalence of Non-Tuberculous Mycobacterial Infections among Tuberculosis Suspects in Nigeria
por: Aliyu, Gambo, et al.
Publicado: (2013)

Final HIV status outcome for HIV-exposed infants at 18 months of age in nine states and the Federal Capital Territory, Nigeria
por: Adelekan, Babatunde, et al.
Publicado: (2022)

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study
por: Ndjeka, Norbert, et al.
Publicado: (2022)

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
por: Decroo, Tom, et al.
Publicado: (2022)

Optimising Mycobacterium tuberculosis detection in resource limited settings
por: Alfred, Nwofor, et al.
Publicado: (2014)

Assuring the quality of diagnostic testing: The future is now
por: Nkengsong, John, et al.
Publicado: (2016)

The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance
por: Van Deun, Armand, et al.
Publicado: (2020)

Preliminary Report on HIV-1 Vaccine Preparedness in Nigeria: Advantages of Recruiting University Students
por: Edubio, Abigail, et al.
Publicado: (2010)

Course of Adverse Events during Short Treatment Regimen in Patients with Rifampicin-Resistant Tuberculosis in Burundi
por: Ciza, François, et al.
Publicado: (2020)

Moxifloxacin concentration correlate with QTc interval in rifampicin-resistant tuberculosis patients on shorter treatment regimens
por: Kusmiati, Tutik, et al.
Publicado: (2022)

Nine Months' Work and Progress
Publicado: (1918)

Report of Nine Months' Work
Publicado: (1920)

Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria
por: Avong, Yohanna Kamabi, et al.
Publicado: (2015)

Demography and the dual epidemics of tuberculosis and HIV: Analysis of cross-sectional data from Sub-Saharan Africa
por: Aliyu, Gambo, et al.
Publicado: (2018)

Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria
por: Ndembi, Nicaise, et al.
Publicado: (2020)

Prevalence and risk factors for obesity among elderly patients living with HIV/AIDS in a low-resource setting
por: Dakum, Patrick, et al.
Publicado: (2021)

HIV Viral Dynamics of Lopinavir/Ritonavir Monotherapy as Second-Line Treatment: A Prospective, Single-Arm Trial
por: Claassen, Cassidy W., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_aa6vhk21ve6ofbseihtbne2krd